In­s­med's an­ti-in­flam­ma­to­ry drug wins break­through sta­tus; Ky­owa Kirin backs new fund from 4BIO Cap­i­tal

→ A mixed mid-stage read­out of In­smed‘s an­ti-in­flam­ma­to­ry drug, INS1007, read more like a win giv­en the low ex­pec­ta­tions for the tri­al back in Feb­ru­ary. Now, the FDA has stamped the drug with a vote of con­fi­dence, grant­i­ng it break­through ther­a­py sta­tus for the treat­ment of adult pa­tients with non-cys­tic fi­bro­sis bronchiec­ta­sis for re­duc­ing ex­ac­er­ba­tions. The drug, now chris­tened brenso­cat­ib, is an oral, re­versible in­hibitor of dipep­tidyl pep­ti­dase 1 (DPP1).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER